Hepaxa(TM) is a medical food product effective in the dietary management of steatosis in early-stage NAFLD patients. A recent RCT has established Hepaxa(TM) as safe and shown the patients most likely to respond to be those with FLI (fatty liver index) score of 40+. The effective minimum dose threshold for EPA/DHA is 2.5mg daily. Hepaxa(TM) meets this threshold. Hepaxa(TM) has also been effectively filtered to remove unwanted lipids, pollutants and PCB-153 (shown to be detrimental to NAFLD/liver patients).
*BASF is one of the world's largest chemical company and the innovator (Pronova, Norway) of several novel omega-based products over the past several decades.
*DIEM Labs is dedicated to providing new and novel solutions to unique patient needs.
*Medical Foods should always be administered under the supervision of a healthcare professional.
221 Dino Drive
Ann Arbor, Michigan 48103